Vendor Intelligence Report: Guangzhou Yuao Trading

Published 3 Jul 2026. 21-page investigative report on who is behind Guangzhou Yuao Trading: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 4 Finnrick lab tests, Guangzhou Yuao Trading shows 4 passes and 0 failures — an overall pass rate of 100%. That headline is strong, but narrow: every supplied Finnrick result is for retatrutide. On the available data, Yuao is a reasonable evidence-backed option for retatrutide specifically; other peptides remain outside the Finnrick evidence base.

The corporate and channel record is much weaker than the retatrutide testing record. Investigators could not verify a registered legal entity, officers, personnel profile, or facility address under the Guangzhou Yuao Trading name. The supplied Alibaba profile returned 404, the Global Sources page loaded blank, the obvious vendor domain was unregistered, and the Hong Kong-code WhatsApp contact remains unresolved.

The most concrete regulatory trace surfaced under a separately named Guangzhou cross-border e-commerce company, not under Yuao itself. DailyMed and NDClist records tie that lead to retatrutide-related listings, but the report does not treat it as the legal operator behind Guangzhou Yuao Trading without shared invoices, COAs, addresses, personnel, or infrastructure.

Public reputation signals are also thin: no sanctions, litigation, FDA enforcement action, or affiliate-promotion network was documented, but community visibility is low and prior third-party reputation material became inaccessible. Cached manufacturer, plant-capacity, GMP, FDA, ISO 9001, and Halal claims remain unverified from the live public footprint.

Inside the full report:

  • Appendix A — Finnrick Laboratory Data, including the retatrutide line record, methodology-divergence view, and rating trajectory visuals
  • Dated screenshots of the Alibaba 404, blank Global Sources page, Wayback no-snapshot result, and unregistered gzyuao.com WHOIS status
  • DailyMed and NDClist exhibits for the separately named Guangzhou NDC-labeler and packager lead
  • Registry and identity-search crosswalk covering Yuao name variants, the +852 WhatsApp anchor, and China/Hong Kong dead ends
  • Claims-verification matrix for manufacturer status, plant capacity, GMP, FDA, ISO 9001, and Halal references
  • Market-visibility and affiliate-promotion scan across Reddit, GLP-1 Forum material, X/web coupon searches, and PeptideBenchmark captures

Risk assessment

  • Corporate identity and legal-traceability risk — high: Guangzhou Yuao Trading is not verified in searched registries; no officers, address, or personnel were found, and the possible Guangzhou Yixin link remains unconfirmed.
  • Official-channel instability and authenticity risk — high: Alibaba returns 404, Global Sources is blank, and gzyuao.com is unregistered; no official-channel list or anti-counterfeit verification signals were found.
  • Unverified manufacturer and certification-claim risk — medium: Cached Global Sources text claimed plant capacity and GMP/FDA/ISO 9001/Halal credentials, but no certificate numbers, issuer validation, facility address, or audit documents were located.
  • Retatrutide batch-traceability and shipment-continuity risk — medium: Retatrutide has 4 pass / 0 fail and Finnrick rating 83.06%, but purchases still route through an opaque cross-border identity with an unverified Yixin relationship.
  • Non-retatrutide product-evidence gap — medium: Finnrick data covers retatrutide only; quality confidence should not be extended to any other peptide sold or offered by the vendor.